NGENF Stock NervGen Pharma (NGENF, $2.58) Moving Average Convergence Divergence (MACD) Histogram turned negative on July 25, 2025

GET DAILY SIGNALS

Get AI intraday signals

NGENF - NervGen Pharma Corp.

MACD signal

View

Odds of DOWN Trend

Price: $2.58

Daily change: -$0.12 (-4.44%)

Daily volume: 99.4K

Capitalization: $187.7M

Industry: Biotechnology

NGENF sees MACD Histogram crosses below signal line

NGENF saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on July 25, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 48 instances where the indicator turned negative. In of the 48 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 24, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on NGENF as a result. In of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

NGENF moved below its 50-day moving average on July 16, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NGENF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for NGENF entered a downward trend on August 15, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 18 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

NGENF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. NGENF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NGENF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: NGENF's P/B Ratio (151.515) is slightly higher than the industry average of (19.528). P/E Ratio (0.000) is within average values for comparable stocks, (52.377). NGENF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.945). Dividend Yield (0.000) settles around the average of (0.042) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (294.394).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.